Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been assigned an average recommendation of "Buy" from the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $59.82.

Several equities analysts recently weighed in on the company. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $55.00 target price on the stock. UBS Group lowered their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Citigroup began coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective on the stock. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective on the stock in a research report on Monday, June 2nd. Finally, Guggenheim restated a "buy" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $45.87 on Friday. The company has a market capitalization of $2.99 billion, a PE ratio of -14.80 and a beta of 2.07. The business's fifty day moving average is $35.05 and its 200 day moving average is $35.77. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. Kymera Therapeutics's quarterly revenue was up 114.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.69) earnings per share. On average, sell-side analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other news, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the transaction, the chief executive officer now directly owns 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,349 shares of company stock valued at $2,334,301. 16.01% of the stock is currently owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in shares of Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after purchasing an additional 5,771 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock valued at $24,535,000 after purchasing an additional 491,737 shares during the period. Millennium Management LLC boosted its holdings in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company's stock valued at $13,972,000 after purchasing an additional 394,562 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock valued at $849,000 after purchasing an additional 1,833 shares during the period. Finally, Eventide Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 15.2% in the first quarter. Eventide Asset Management LLC now owns 525,138 shares of the company's stock valued at $14,373,000 after purchasing an additional 69,410 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.